Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below 200 Day Moving Average – Here’s What Happened

Posted by Jeff Wilder on Aug 5th, 2026

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.45 and traded as low as $3.31. Cryo-Cell International shares last traded at $3.48, with a volume of 6,590 shares trading hands.

Cryo-Cell International Stock Performance

The business has a 50 day moving average price of $3.51 and a two-hundred day moving average price of $3.45. The stock has a market cap of $29.34 million, a PE ratio of -12.13 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $0.07 EPS for the quarter. The business had revenue of $7.78 million for the quarter.

Institutional Investors Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

(Get Free Report)

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.